Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Groupe Hospitalier Pitie Salpetriere, |
RCV000496203 | SCV000586747 | pathogenic | Smith-Magenis syndrome | 2017-01-06 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001008262 | SCV001168028 | pathogenic | not provided | 2022-08-12 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28708303) |
Institute for Genomic Statistics and Bioinformatics, |
RCV000496203 | SCV002107177 | pathogenic | Smith-Magenis syndrome | 2022-03-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001008262 | SCV003461720 | pathogenic | not provided | 2023-10-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys989Serfs*74) in the RAI1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAI1 are known to be pathogenic (PMID: 21857958, 24715852). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with a neurodevelopmental condition (PMID: 28708303). ClinVar contains an entry for this variant (Variation ID: 431118). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002527127 | SCV003581393 | pathogenic | Inborn genetic diseases | 2021-09-29 | criteria provided, single submitter | clinical testing | The c.2966_2969delAAGA (p.K989Sfs*74) alteration, located in exon 3 (coding exon 1) of the RAI1 gene, consists of a deletion of 4 nucleotides from position 2966 to 2969, causing a translational frameshift with a predicted alternate stop codon after 74 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This mutation was identified once in a cohort of individuals with presumed genetic neurodevelopmental disorders via whole exome sequencing (Chérot, 2018). Based on the available evidence, this alteration is classified as pathogenic. |
Clinical Genetics Laboratory, |
RCV001008262 | SCV005199043 | pathogenic | not provided | 2022-07-21 | criteria provided, single submitter | clinical testing |